Patent ID: 8883822

Claim:
A compound, or pharmaceutically acceptable salt thereof, of Formula I: wherein: R 1 and R 2 are independently selected from the group consisting of H, lower alkyl, halide, —(C 1-9 alkyl) n aryl(R 6 ) q , —(C 1-9 alkyl) n heteroaryl(R 7 ) q , —(C 1-9 alkyl) n heterocyclyl(R 8 ) q , —(C 1-9 alkyl) n N(R 9 ) 2 , —OR 10 and —NHC(═O)R 11 ; R 3 is selected from the group consisting of H, halide and lower alkyl; with the proviso that at least two of R 1 , R 2 and R 3 are H; R 4 and R 5 are independently selected from the group consisting of H, —C(═O)N(R 12 ) 2 , -aryl(R 13 ) q , -heterocyclyl(R 14 ) q , and -heteroaryl(R 15 ) q ; with the proviso that at least one of R 4 and R 5 is H; each R 6 is a substituent attached to the aryl ring and independently selected from the group consisting of H, —C 1-9 alkyl, halide, CF 3 and CN; each R 7 is a substituent attached to the heteroaryl ring and independently selected from the group consisting of H, —C 1-9 alkyl, halide, CF 3 and CN; each R 8 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, halide, —(C 1-3 alkyl) n aryl(R 6 ) q , and —C 1-4 alkyl; each R 9 is independently selected from the group consisting of H, —C 1-9 alkyl, —(C 1-3 alkyl) n aryl(R 6 ) q , —(C 1-3 alkyl) n carbocyclyl and —(C 1-9 alkyl)N(R 16 ) 2 ; alternatively, two adjacent R 9 or two adjacent R 12 , may be taken together with the atoms to which they are attached to form a heterocyclyl(R 17 ) q ; R 10 is selected from the group consisting of H, —CF 3 , —(C 1-3 alkyl) n aryl(R 6 ) q , and —C 1-9 alkyl; R 11 is selected from the group consisting of —(C 1-3 alkyl) n aryl(R 6 ) q , —(C 1-3 alkyl) n carbocyclyl, —C 1-9 alkyl and —CF 3 ; each R 12 is independently selected from the group consisting of H, —(C 1-9 alkyl) n aryl(R 6 ) q and —C 1-9 alkyl; each R 13 is a substituent attached to the aryl ring and independently selected from the group consisting of H, halide, —CF 3 , CN, —(C 1-3 alkyl) n heterocyclyl(R 8 ) q , —(C 1-9 alkyl) n N(R 9 ) 2 and —(C 1-9 alkyl) n NHSO 2 R 18 ; each R 14 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, lower alkyl, halide, —CF 3 and CN; each R 15 is a substituent attached to the heteroaryl ring and independently selected from the group consisting of H, lower alkyl, halide, —CF 3 , CN, —C(═O)(C 1-3 alkyl), —(C 1-9 alkyl) n N(R 9 ) 2 and —(C 1-9 alkyl) n NHSO 2 R 18 ; each R 16 is independently selected from the group consisting of H and lower alkyl; each R 17 is a substituent attached to the heterocyclyl ring and independently selected from the group consisting of H, —(C 1-9 alkyl) n aryl(R 6 ) q , and —C 1-9 alkyl; each R 18 is a lower alkyl; A is C; each q is an integer of 1 to 5; each n is an integer of 0 or 1; and with the proviso that Formula I is not a structure selected from the group consisting of: